Table 2.
Incidence of conjunctival hyperemia per investigator assessment, by study visit (safety population treated with LBN 0.024%)
| Study visit | Any hyperemia/moderate hyperemiaa
Eyes, n (%) |
|
|---|---|---|
| Study eye (N = 130)b | Treated fellow eye (N = 126)b | |
| Baseline | 20 (15.4)/0 (0.0) | 18 (14.3)/0 (0.0) |
| Week 4 | 27 (20.8)/0 (0.0) | 24 (19.0)/0 (0.0) |
| Week 8 | 26 (20.2)/0 (0.0) | 24 (19.2)/0 (0.0) |
| Week 12 | 24 (18.8)/2 (1.6) | 22 (17.7)/2 (1.6) |
| Week 16 | 24 (19.0)/1 (0.8) | 21 (17.2)/1 (0.8) |
| Week 20 | 25 (19.8)/1 (0.8) | 22 (18.0)/1 (0.8) |
| Week 24 | 25 (19.8)/1 (0.8) | 22 (18.0)/1 (0.8) |
| Week 28 | 22 (17.5)/1 (0.8) | 22 (18.0)/2 (1.6) |
| Week 32 | 23 (18.4)/1 (0.8) | 22 (18.2)/1 (0.8) |
| Week 36 | 22 (17.9)/1 (0.8) | 20 (16.8)/1 (0.8) |
| Week 40 | 22 (18.0)/1 (0.8) | 20 (16.9)/1 (0.8) |
| Week 44 | 23 (18.9)/1 (0.8) | 20 (16.9)/1 (0.8) |
| Week 48 | 22 (18.0)/1 (0.8) | 20 (16.9)/1 (0.8) |
| Week 52 | 22 (18.2)/1 (0.8) | 20 (17.1)/1 (0.9) |
LBN latanoprostene bunod
aThere were no instances of severe hyperemia in any treated eye during the study
bData missing for the study eye and the treated fellow eye for one subject at week 8; two subjects at week 12; four subjects at weeks 16, 20, 24, and 28; five subjects at week 32; seven subjects at week 36; eight subjects at weeks 40, 44, and 48; and nine subjects at week 52